OUR STORY
In 2013, the Biomaterials and Bioengineering Laboratory of the French National Institute for Health and Medical Research (Inserm UMR 1121), co-directed by our CSO, Dr. Philippe Lavalle, discovered the antimicrobial properties of the anti-inflammatory coatings we were working on. Between 2016 and 2018, we worked to develop our technology with the support of SATT Conectus .
In 2019, our CEO, Dr. Nihal Engin Vrana, together with 2 collaborators, Dr. Philippe Lavalle and Dr. Angela Mutschler created SPARTHA Medical and were then incubated at SEMIA. In 2021, SPARTHA Medical obtained CIR accreditation for research and development (R&D) after scientific and technical expertise.
End of 2021, SPARTHA Medical is laureate of the EIC Accelerator. This grant aims to help to deploy our innovation and start clinical evaluations. The project is called SPARTHACUS.
SPARTHA Medical supports the Sustainable Development Goals
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or SPARTHA Medical. Neither the European Union nor the granting authority can be held responsible for them.
CO-FOUNDERS
Scientific Advisory Board
Strategic Advisory Board
Prof. Pierre Schaaf
University of Strasbourg
Co-inventor \ Surface chemistry Expert
Prof. Ghaemmaghami
University of Nottingham
Clinical Immunology Expert
Prof. Florent Meyer
University of Strasbourg
Periodontal Surgeon
Severine Sigrist
CEO Defymed
Class III Medical device developper \ Reglementation
Guillaume Vetter Genoud
Director of Deep Tech
SEMIA (Finance)
Agnès Dupret-Bories
Chief Surgeon UITC
clinical trials
OUR PARTNERS
RESEARCH SUPPORTS
Research Unit UMR S1110
Institute for Research on Viral and Hepatic Diseases